{
  "doc": {
    "accession": "0001193125-23-194715",
    "filingType": "8-K",
    "filedDate": "2023-07-20",
    "companyName": "Alnylam Pharmaceuticals, Inc.",
    "cik": "1178670"
  },
  "event": {
    "kind": "Collaboration",
    "secItem": "Item 1.01",
    "headline": "Entry into a Material Definitive Agreement.",
    "summary": "(the “”), entered into a Collaboration and License Agreement (the “”) with F.",
    "totalValueUSD": 2500000000,
    "effectiveDate": "2023-07-20"
  },
  "provenance": {
    "documents": [
      {
        "role": "primary",
        "filename": "primary.html",
        "sourceUrl": "https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm",
        "sha256": "25010a825d8c244ee15650da75eff795a4839badb15e20b0cf6dc8a8e3acd091"
      },
      {
        "role": "exhibit",
        "filename": "d448801dex991_7.htm",
        "sourceUrl": "https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm",
        "sha256": "93576a262d260d5aaed1c9c1a2142482fb057514ffbf9aff597e3cd01adc3757"
      }
    ]
  },
  "evidence": [
    {
      "sourceFile": "chunk_0001.txt",
      "sourceUrl": "https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm",
      "sourceSection": "",
      "selector": "chunk:chunk_0001.txt",
      "snippet": "\n\n=== SOURCE: primary.html ===\n\nUNITED STATES\nSECURITIES AND EXCHANGE COMMISSION\nWASHINGTON, D.C. 20549\nCURRENT REPORT\nPursuant to Section 13 or 15(d)\nof the Securities Exchange Act of 1934\nDate of re",
      "field": "doc.accession"
    },
    {
      "sourceFile": "chunk_0001.txt",
      "sourceUrl": "https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm",
      "sourceSection": "",
      "selector": "chunk:chunk_0001.txt",
      "snippet": "\n\n=== SOURCE: primary.html ===\n\nUNITED STATES\nSECURITIES AND EXCHANGE COMMISSION\nWASHINGTON, D.C. 20549\nCURRENT REPORT\nPursuant to Section 13 or 15(d)\nof the Securities Exchange Act of 1934\nDate of re",
      "field": "doc.filingType"
    },
    {
      "sourceFile": "chunk_0001.txt",
      "sourceUrl": "https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm",
      "sourceSection": "",
      "selector": "chunk:chunk_0001.txt",
      "snippet": "e Act of 1934\nDate of report (Date of earliest event reported): July 26, 2023 ( July 21, 2023 )\nAlnylam Pharmaceuticals, Inc.\n(Exact name of registrant as specified in its c",
      "field": "doc.filedDate"
    },
    {
      "sourceFile": "chunk_0001.txt",
      "sourceUrl": "https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm",
      "sourceSection": "",
      "selector": "chunk:chunk_0001.txt",
      "snippet": "te of report (Date of earliest event reported): July 26, 2023 ( July 21, 2023 )\nAlnylam Pharmaceuticals, Inc.\n(Exact name of registrant as specified in its charter)\nDelaware\n001-36407\n77-06",
      "field": "doc.companyName"
    },
    {
      "sourceFile": "chunk_0001.txt",
      "sourceUrl": "https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm",
      "sourceSection": "",
      "selector": "chunk:chunk_0001.txt",
      "snippet": "\n\n=== SOURCE: primary.html ===\n\nUNITED STATES\nSECURITIES AND EXCHANGE COMMISSION\nWASHINGTON, D.C. 20549\nCURRENT REPORT\nPursuant to Section 13 or 15(d)\nof the Securities Exchange Act of 1934\nDate of re",
      "field": "doc.cik"
    },
    {
      "sourceFile": "chunk_0002.txt",
      "sourceUrl": "https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm",
      "sourceSection": "=== Item 1.01 ===",
      "selector": "chunk:chunk_0002.txt",
      "snippet": "July 21, 2023 (the “”), Alnylam Pharmaceuticals, Inc. (the “”), entered into a Collaboration and License Agreement (the “”) with F. Roche Ltd. (“”) and Genentech, Inc. (“,”",
      "field": "event.kind"
    },
    {
      "sourceFile": "chunk_0001.txt",
      "sourceUrl": "https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm",
      "sourceSection": "",
      "selector": "chunk:chunk_0001.txt",
      "snippet": "al accounting standards provided pursuant to Section 13(a) of the Exchange Act.\nItem 1.01\tEntry into a Material Definitive Agreement.\n\n=== Item 1.01 ===\n\nEntry into a Ma",
      "field": "event.secItem"
    },
    {
      "sourceFile": "chunk_0001.txt",
      "sourceUrl": "https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm",
      "sourceSection": "",
      "selector": "chunk:chunk_0001.txt",
      "snippet": "ing standards provided pursuant to Section 13(a) of the Exchange Act.\nItem 1.01\tEntry into a Material Definitive Agreement.\n\n=== Item 1.01 ===\n\nEntry into a Material Definitive Agreement.\nOn July 21, ",
      "field": "event.headline"
    },
    {
      "sourceFile": "chunk_0002.txt",
      "sourceUrl": "https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm",
      "sourceSection": "=== Item 1.01 ===",
      "selector": "chunk:chunk_0002.txt",
      "snippet": "Definitive Agreement.\nOn July 21, 2023 (the “”), Alnylam Pharmaceuticals, Inc. (the “”), entered into a Collaboration and License Agreement (the “”) with F. Roche Ltd. (“”) and Genentech, Inc. (“,” ea",
      "field": "event.summary"
    },
    {
      "sourceFile": "chunk_0002.txt",
      "sourceUrl": "https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm",
      "sourceSection": "=== Item 1.01 ===",
      "selector": "chunk:chunk_0002.txt",
      "snippet": "lion to the Company. In addition, the Company will be eligible to receive up to $2.5 billion in contingent payments based on the achievement of specified development, regul",
      "field": "event.totalValueUSD"
    },
    {
      "sourceFile": "chunk_0001.txt",
      "sourceUrl": "https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm",
      "sourceSection": "",
      "selector": "chunk:chunk_0001.txt",
      "snippet": "\n\n=== SOURCE: primary.html ===\n\nUNITED STATES\nSECURITIES AND EXCHANGE COMMISSION\nWASHINGTON, D.C. 20549\nCURRENT REPORT\nPursuant to Section 13 or 15(d)\nof the Securities Exchange Act of 1934\nDate of re",
      "field": "event.effectiveDate"
    },
    {
      "sourceFile": "chunk_0001.txt",
      "sourceUrl": "https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm",
      "sourceSection": "",
      "selector": "chunk:chunk_0001.txt",
      "snippet": "te of report (Date of earliest event reported): July 26, 2023 ( July 21, 2023 )\nAlnylam Pharmaceuticals, Inc.\n(Exact name of registrant as specified in its charter)\nDelaware\n001-36407\n77-06",
      "field": "partnership.partnerA"
    },
    {
      "sourceFile": "chunk_0002.txt",
      "sourceUrl": "https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm",
      "sourceSection": "=== Item 1.01 ===",
      "selector": "chunk:chunk_0002.txt",
      "snippet": "Inc. (the “”), entered into a Collaboration and License Agreement (the “”) with F. Roche Ltd. (“”) and Genentech, Inc. (“,” each of Roche Basel and Genentech, individually",
      "field": "partnership.partnerB"
    },
    {
      "sourceFile": "chunk_0002.txt",
      "sourceUrl": "https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm",
      "sourceSection": "=== Item 1.01 ===",
      "selector": "chunk:chunk_0002.txt",
      "snippet": "“”), pursuant to which the Company and Roche established a worldwide, strategic collaboration for the joint development of pharmaceutical products containing zilebesiran, the Company’s proprietary siR",
      "field": "partnership.scope"
    },
    {
      "sourceFile": "chunk_0002.txt",
      "sourceUrl": "https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm",
      "sourceSection": "=== Item 1.01 ===",
      "selector": "chunk:chunk_0002.txt",
      "snippet": "ly and collectively, “”), pursuant to which the Company and Roche established a worldwide, strategic collaboration for the joint development of pharmaceutical products c",
      "field": "partnership.territory"
    },
    {
      "sourceFile": "chunk_0002.txt",
      "sourceUrl": "https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm",
      "sourceSection": "=== Item 1.01 ===",
      "selector": "chunk:chunk_0002.txt",
      "snippet": "ted States (the “”).\nUnder the Agreement, Roche will make an upfront payment of $310 million to the Company. In addition, the Company will be eligible to receive up to $2.5",
      "field": "partnership.upfrontPaymentUSD"
    },
    {
      "sourceFile": "chunk_0002.txt",
      "sourceUrl": "https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm",
      "sourceSection": "=== Item 1.01 ===",
      "selector": "chunk:chunk_0002.txt",
      "snippet": "lion to the Company. In addition, the Company will be eligible to receive up to $2.5 billion in contingent payments based on the achievement of specified development, regul",
      "field": "partnership.milestonesUSD"
    },
    {
      "field": "provenance.documents",
      "sourceFile": "chunk_0001.txt",
      "sourceUrl": "https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm",
      "sourceSection": "",
      "selector": "chunk:chunk_0001.txt",
      "snippet": "\n\n=== SOURCE: primary.html ===\n\nUNITED STATES\nSECURITIES AND EXCHANGE COMMISSION\nWASHINGTON, D.C. 20549\nCURRENT REPORT\nPursuant to Section 13 or 15(d)\nof the Securities Exchange Act of 1934\nDate of re"
    },
    {
      "field": "provenance.documents",
      "sourceFile": "chunk_0001.txt",
      "sourceUrl": "https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm",
      "sourceSection": "",
      "selector": "chunk:chunk_0001.txt",
      "snippet": "\n\n=== SOURCE: primary.html ===\n\nUNITED STATES\nSECURITIES AND EXCHANGE COMMISSION\nWASHINGTON, D.C. 20549\nCURRENT REPORT\nPursuant to Section 13 or 15(d)\nof the Securities Exchange Act of 1934\nDate of re"
    }
  ],
  "validation": {
    "hardConstraints": [],
    "crossField": []
  },
  "partnership": {
    "partnerA": "Alnylam Pharmaceuticals, Inc.",
    "partnerB": "F. Hoffmann-La Roche Ltd.",
    "scope": "collaboration for the joint development of pharmaceutical products containing zilebesiran, the Company’s proprietary siRNA therapeutic targeting liver-expressed angiotensinogen or (“”).",
    "territory": "worldwide",
    "upfrontPaymentUSD": 310000000,
    "milestonesUSD": 2500000000
  }
}
